These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23651089)

  • 1. Ask the experts: past, present and future of the rule of five.
    Baell J; Congreve M; Leeson P; Abad-Zapatero C
    Future Med Chem; 2013 May; 5(7):745-52. PubMed ID: 23651089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Going further than Lipinski's rule in drug design.
    Walters WP
    Expert Opin Drug Discov; 2012 Feb; 7(2):99-107. PubMed ID: 22468912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the medicinally relevant chemical space with compound libraries.
    López-Vallejo F; Giulianotti MA; Houghten RA; Medina-Franco JL
    Drug Discov Today; 2012 Jul; 17(13-14):718-26. PubMed ID: 22515962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of blockbuster drugs under the rule-of-five.
    Giménez BG; Santos MS; Ferrarini M; Fernandes JP
    Pharmazie; 2010 Feb; 65(2):148-52. PubMed ID: 20225662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do Drug-likeness Rules Apply to Oral Prodrugs?
    Protti ÍF; Rodrigues DR; Fonseca SK; Alves RJ; de Oliveira RB; Maltarollo VG
    ChemMedChem; 2021 May; 16(9):1446-1456. PubMed ID: 33471444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-lipid interaction evaluation: why a 19th century solution?
    Ribeiro MM; Melo MN; Serrano ID; Santos NC; Castanho MA
    Trends Pharmacol Sci; 2010 Oct; 31(10):449-54. PubMed ID: 20727600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five.
    Stegemann S; Moreton C; Svanbäck S; Box K; Motte G; Paudel A
    Drug Discov Today; 2023 Feb; 28(2):103344. PubMed ID: 36442594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of specific "drug-like property" rules for carboxylate-containing oral drug candidates.
    Böcker A; Bonneau PR; Hucke O; Jakalian A; Edwards PJ
    ChemMedChem; 2010 Dec; 5(12):2102-13. PubMed ID: 20979082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of the Physicochemical Properties of Acaricides Based on Lipinski's Rule of Five.
    Chen X; Li H; Tian L; Li Q; Luo J; Zhang Y
    J Comput Biol; 2020 Sep; 27(9):1397-1406. PubMed ID: 32031890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of ALOGPS 2.1 to predict log D distribution coefficient for Pfizer proprietary compounds.
    Tetko IV; Poda GI
    J Med Chem; 2004 Nov; 47(23):5601-4. PubMed ID: 15509156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing a drug-like natural product library.
    Quinn RJ; Carroll AR; Pham NB; Baron P; Palframan ME; Suraweera L; Pierens GK; Muresan S
    J Nat Prod; 2008 Mar; 71(3):464-8. PubMed ID: 18257534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical view of 'druggability'.
    Keller TH; Pichota A; Yin Z
    Curr Opin Chem Biol; 2006 Aug; 10(4):357-61. PubMed ID: 16814592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries.
    Dobson PD; Patel Y; Kell DB
    Drug Discov Today; 2009 Jan; 14(1-2):31-40. PubMed ID: 19049901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reporting data from high-throughput screening of small-molecule libraries.
    Inglese J; Shamu CE; Guy RK
    Nat Chem Biol; 2007 Aug; 3(8):438-41. PubMed ID: 17637769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods.
    Houghten RA; Pinilla C; Giulianotti MA; Appel JR; Dooley CT; Nefzi A; Ostresh JM; Yu Y; Maggiora GM; Medina-Franco JL; Brunner D; Schneider J
    J Comb Chem; 2008; 10(1):3-19. PubMed ID: 18067268
    [No Abstract]   [Full Text] [Related]  

  • 16. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates.
    Doak BC; Over B; Giordanetto F; Kihlberg J
    Chem Biol; 2014 Sep; 21(9):1115-42. PubMed ID: 25237858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating physiochemical properties of FDA-approved orally administered drugs.
    Reese TC; Devineni A; Smith T; Lalami I; Ahn JM; Raj GV
    Expert Opin Drug Discov; 2024 Feb; 19(2):225-238. PubMed ID: 37921049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug discovery beyond the 'rule-of-five'.
    Zhang MQ; Wilkinson B
    Curr Opin Biotechnol; 2007 Dec; 18(6):478-88. PubMed ID: 18035532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Rule of Five revisited: applying log D in place of log P in drug-likeness filters.
    Bhal SK; Kassam K; Peirson IG; Pearl GM
    Mol Pharm; 2007; 4(4):556-60. PubMed ID: 17530776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automated medicinal chemistry.
    Koppitz M; Eis K
    Drug Discov Today; 2006 Jun; 11(11-12):561-8. PubMed ID: 16713909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.